Introducing Steve Ferguson, Medix Biochemica’s new CEO
We are happy to introduce our new CEO since January 1st, 2020: Steve Ferguson.
Steve joined Medix Biochemica from Thermo Fisher Scientific’s ImmunoDiagnostics Division, where he had been Vice President of European Commercial Operations. Prior to joining Thermo Fisher Scientific, Steve had held various management positions in the pharmaceutical industry.
Medix Biochemica has significant international growth plans in the in vitro diagnostics industry and we could not be happier that Steve is joining our family and helping us and our customers achieve continued success.
Read below Steve’s short interview:
In your own words, what do you do?
I joined Medix to build on a successful business, to fulfill the ambition of the Board and to establish Medix Biochemica Group as the clear leader in the eyes of our customers. I want to deliver on our ambition to be the number one supplier of critical raw materials to the IVD industry. As CEO, my role is to ensure we have a clear plan in place, and all our people, assets and investments are aligned to deliver that ambition.
What would you say makes Medix Biochemica stand out among other companies?
The quality of our products, the expertise of our people, and our ability to scale manufacturing in the three regions where our customers need us: Europe, the US, and China. New regulations mean our desire to serve our customers and consolidate the supply chain is perfectly aligned to the needs of the IVD industry. IVD regulation is a burden to our customers and it means they must have secure and reliable raw material suppliers. We are in a great position to help our customers as they are going through change themselves.
How does Medix Biochemica’s future look like?
Bright and fast-paced! Through commercial excellence, pipeline acceleration and inorganic acquisition, we will broaden our offering to IVD customers and become the most relevant supplier to them. The acquisition of Lee Bio Solutions in 2019 sees our first step in widening our customer offering. That is the first of many carefully planned acquisitions, and we will intensify our actions here in 2020. The Medix group is expanding and the Medix family is growing. This should be a fun journey for everyone at Medix!